2020-03-31

[#DIV28SUPER] APA 2020 Convention Updates

Hi All,

I hope everyone is doing well and staying healthy in these strange times.

Just wanted to provide a brief update on planning with respect to APA Convention. As of now, communication from the APA programming group is that plans for convention in August are still ongoing. However, developments are being monitored and updates will be provided about the status of convention as they may occur. The best place to find the most recent updates is the APA 2020 website https://convention.apa.org

One particularly relevant recent piece of information is that the opening of convention registration and housing sign up has been delayed until May 15th.

Feel free to reach out with any questions and stay safe everyone.

Best,
Justin
Division 28 2020 Convention Program Chair


---------------------------------------------------------
Justin C. Strickland, Ph.D.
Postdoctoral Fellow
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Phone: (410) 550-1975

[#DIV28SUPER] Council Summary

Dear Division 28 Colleagues-
I hope this email finds all of you doing okay in these turbulent times.
Please find attached a summary of the APA Council of Representatives meeting from last month. If you would like greater detail on what happened at the meeting, please feel free to reach out to me or click the link at the end of the summary to download detailed, draft minutes.
-Bill Stoops, APA Division 28 Council Representative.
              
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
Departments of Behavioral Science, Psychiatry and Psychology
Center on Drug and Alcohol Research
University of Kentucky

Director
Regulatory Knowledge and Support Core-Center for Clinical and Translational Science
Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2020-03-25

[#DIV28SUPER] Federal Register :: Controls To Enhance the Cultivation of Marihuana for Research in the United States

Hello Division 28 Members,

 

The DEA recently posted a proposed change to the Controlled Substances Act in order to "facilitate the cultivation of marihuana for research purposes and other licit purposes." Comments can be posted now through May 22, 2020 using the link below:

 

https://www.federalregister.gov/documents/2020/03/23/2020-05796/controls-to-enhance-the-cultivation-of-marihuana-for-research-in-the-united-states?et_rid=16761238&et_cid=3257445

 

Dr. Volkow testified about this matter recently:

 

http://click.aaas.sciencepubs.org/?qs=a1a064a724e7061b69e92c41e04094bb4ad2832a9bc2fd039603493a5cff075827892001c3c5ded0a2ac4ce9e773d9cea8808de48564e539

 

I'm also attaching comments that were submitted on behalf of APA.

 

I hope you are all doing well!

 

Thanks, Wendy

 

Wendy J. Lynch, Ph.D.

President, APA Division 28 (Psychopharmacology and Substance Abuse)

Associate Professor of Psychiatry and Neurobehavioral Sciences

Physical Address: 450 Ray C. Hunt Drive (Aurbach Building), Room G164

Mailing Address: PO Box 801402, Charlottesville, VA 22904-1402

434-243-0580 (office)

434-249-3699 (cell)

 

 

 

From: Mumford, Geoff <gmumford@apa.org>
Sent: Wednesday, March 25, 2020 11:39 AM
To: Lynch, Wendy J (wjl6w) <wjl6w@virginia.edu>
Cc: Ronald Wood <ronaldwood@gmail.com>
Subject: RE: [EXEC28CC] Federal Register :: Controls To Enhance the Cultivation of Marihuana for Research in the United States

 

Sure Wendy, here you go!  Hope you're safe and healthy and hanging in there!

Best,

-geoff

 

 

From: Lynch, Wendy J (wjl6w) <wjl6w@virginia.edu>
Sent: Wednesday, March 25, 2020 10:31 AM
To: Mumford, Geoff <gmumford@apa.org>
Subject: Fwd: [EXEC28CC] Federal Register :: Controls To Enhance the Cultivation of Marihuana for Research in the United States

 

Can you please send me the link to APAs statement and I'll forward it to division 28 members. 

 

Thanks! Wendy 

Sent from my iPhone


Begin forwarded message:

From: Ronald Wood <ronaldwood@GMAIL.COM>
Date: March 25, 2020 at 9:45:13 AM EDT
To: "EXEC28CC@LISTS.APA.ORG" <EXEC28CC@LISTS.APA.ORG>
Subject: Re:  [EXEC28CC] Federal Register :: Controls To Enhance the Cultivation of Marihuana for Research in the United States
Reply-To: exec28cc  conference of current executive board members <EXEC28CC@LISTS.APA.ORG>



The APA written testimony is superb.

 

Really proud of the work done by APA  on behalf of research and protection of public health

 

Ron

 

On Wed, Mar 25, 2020 at 9:35 AM Mumford, Geoff <gmumford@apa.org> wrote:

Great minds think alike Ron! We're on it and we submitted a statement for that hearing too...

Best,

-geoff

_________________ exec28cc@lists.apa.org ______________________
executive board division 28 twitter: @apadiv28 join our network


CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

[#DIV28SUPER] FW: Post-doctoral fellowship positions

From: Gipson-Reichardt, Cassandra D. <Cassandra.Gipson-Reichardt@uky.edu>
Sent: Wednesday, March 25, 2020 10:29 AM
To: Lynch, Wendy J (wjl6w) <wjl6w@virginia.edu>
Subject: Post-doctoral fellowship positions

 

Hi Wendy,


Is there any way I can send this job ad for two post-doc positions in my lab around the APA Division 28 listserv? I wasn't sure who to ask. Details are below.

 

Thank you!
Cassie

 

 

Posting Details

Posting Details

Job Title

Postdoctoral Scholar

Requisition Number

DU06566

Department Name

7H460:FAMILY AND COMMUNITY MEDICINE

Work Location

Lexington, KY

Salary Range

$54,704 - $64,008/year

Type of Position

Student

Position Time Status

Full-Time

Required Education

Ph.D.

Required Related Experience

Minimum of 3-4 years experience with rodent handling, conducting literature searches, data analyses, and preparation of scientific manuscripts and grant applications.

Required License/Registration/Certification

None

Physical Requirements

Sitting, standing, working on computer for long periods of time

Shift

Monday – Friday 8a-5p, some weekends required

Job Summary

One project will involve performing whole cell patch clamp electrophysiology as well standard rodent models of drug addiction. The other project will involve examination of astrocyte morphometry and synaptic colocalization. These positions are available in the laboratory of Dr. Cassandra Gipson. The Gipson laboratory is interested in neurobiological underpinnings of nicotine relapse and addiction, as well as cocaine/opioid and nicotine/opioid co-use. More specifically, the lab focuses on examination of neuroimmune mechanisms that contribute to aberrant glutamate signaling during motivated drug seeking. As well, the lab is focused on the relationship between nicotine and ovarian hormones as well as contraceptive estrogen.

One project will involve performing whole cell patch clamp electrophysiology as well standard rodent models of drug addiction. The other project will involve examination of astrocyte morphometry and synaptic colocalization. These positions are available in the laboratory of Dr. Cassandra Gipson. The Gipson laboratory is interested in neurobiological underpinnings of nicotine relapse and addiction, as well as cocaine/opioid and nicotine/opioid co-use. More specifically, the lab focuses on examination of neuroimmune mechanisms that contribute to aberrant glutamate signaling during motivated drug seeking. As well, the lab is focused on the relationship between nicotine and ovarian hormones as well as contraceptive estrogen.

The chosen candidates will have the opportunity to utilize other neuroscience and behavioral techniques such as biosensors, chemogenetics, behavioral economics, and choice procedures. The chosen candidates will also be required to develop fellowship grant applications and will be required to attend 1-2 scientific conferences per year. Ongoing collaborations exist with researchers within the Department of Psychology, Behavioral Science, and with other departments across campus, and it is anticipated that the successful candidate will join in such collaborations.

Salary is commensurate with years of postdoctoral experience in accordance with NIH guidelines set for NRSA stipends (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-070.html)”

Skills / Knowledge / Abilities

Strong neuroscience background with proven publication records.

Does this position have supervisory responsibilities?

No

Preferred Education/Experience

Experience with behavioral testing in rodent models of drug addiction, transgenic animals, chemogenetics, optogenetics, or dendritic spine morphology analysis.

Deadline to Apply

12/31/9999

University Community of Inclusion

The University of Kentucky is committed to a diverse and inclusive workforce by ensuring all our students, faculty, and staff work in an environment of openness and acceptance. We strive to foster a community where people of all backgrounds, identities, and perspectives can feel secure and welcome. We also value the well-being of each of our employees and are dedicated to creating a healthy place to work, learn and live. In the interest of maintaining a safe and healthy environment for our students, employees, patients and visitors the University of Kentucky is a Tobacco & Drug Free campus.

As an Equal Opportunity Employer, we strongly encourage veterans, individuals with disabilities, women, and all minorities to consider our employment opportunities.

Any candidate offered a position may be required to pass pre-employment screenings as mandated by University of Kentucky Human Resources. These screenings may include a national background check and/or drug screen.

Posting Specific Questions

Required fields are indicated with an asterisk (*).

Applicant Documents

Required Documents

1.    Curriculum Vita

2.    Cover Letter

3.    Academic Transcript

Optional Documents

 

 

2020-03-23

[#DIV28SUPER] Fw: Postdoc in Translational Science of Alcohol and HIV at the University of Florida




UNIVERSITY OF FLORIDA -

TRANSLATIONAL SCIENCE TRAINING TO REDUCE THE

IMPACT OF ALCOHOL ON HIV INFECTION

 

OPENING FOR POSTDOCTORAL FELLOW IN T32 TRAINING PROGRAM

 

Multidisciplinary training program focused on alcohol and HIV

Behavioral and clinical interventions

Data science

Neurocognition and brain science

 

Postdocs will work on NIH-funded grants, participate in seminars and training programs,

develop their own research programs and be mentored by outstanding faculty including

Co-Directors Drs. Robert Cook, Robert Leeman and Robert Lucero and colleagues from the following disciplines:  

 

Biostatistics: Drs. Babette Brumback

Clinical & Health Psychology: Drs. Jeff Boissoneault, Ron Cohen, Eric Porges, Catherine Price, Adam Woods

Epidemiology: Drs. Xinguang Chen, Linda Cottler, Mattia Prosperi, Yan Wang

Health Education & Behavior: Drs. JeeWon Cheong, Jalie Tucker

Nursing: Drs. Anna McDaniel, Diana Wilkie

Pathology: Dr. Marco Salemi

Psychiatry/Psychology: Dr. Sara Jo Nixon

 

Funding includes an annual stipend, research/travel expenses and health insurance

Individuals from under represented populations are strongly encouraged to apply

 

Email questions & CV to:

sharct32@phhp.ufl.edu or any program faculty

 

For more information:

http://sharc-research.org/get-involved/t32-training/

 

2020-03-22

[#DIV28SUPER] post-bac RA position in Baltimore, MD

Please circulate to individuals interested in a FT post-baccalaureate research assistant position in Baltimore, Maryland.

 

Thanks,

Richard Yi, Ph.D.

Director, Cofrin Logan Center for Addiction Research and Treatment

Professor, Department of Psychology

University of Kansas, Lawrence, KS 66045

Email: ryi1@ku.edu          Phone: 785-864-6476

https://addiction.ku.edu

 

2020-03-21

[#DIV28SUPER] Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding

Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH

The NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the HHS declared public health emergency for COVID-19. Due to the potential exceptional impact, we want to assure our recipient community that NIH will be doing our part to help you continue your research.

This is a rapidly evolving situation and we will provide updated guidance and information as it becomes available.

https://grants.nih.gov/grants/natural_disasters/corona-virus.htm

 

Guidance

Proposal Submission & Award Management

Human Subjects & Clinical Trials

<image005.png>

Animal Welfare

<image005.png>

- March 19, 2020 

Peer Review

<image006.png>

, in-person NIH peer review meetings are being held in alternate formats. Scientific review officers will be in contact with peer reviewers about these changes.

FAQs

Funding Opportunities Specific to COVID-19

NOT-AI-20-030

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of General Medical Sciences (NIGMS)

NOT-HL-20-757

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

National Heart, Lung, and Blood Institute (NHLBI)

NOT-DA-20-047

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

National Institute on Drug Abuse (NIDA)

Resources

<image005.png>

<image005.png>

<image006.png>

2020-03-19

[#DIV28SUPER] Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus


Notice Number: NOT-DA-20-047 https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html

 

Key Dates
Release Date: March 19, 2020
First Available Due Date: March 19, 2020
Expiration Date: March 31, 2021

Related Announcements

PA-18-935Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)
PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Background

As people across the U.S. and the rest of the world prepare for what could be a pandemic of the 2019 novel coronavirus, or COVID-19, the research community should be alert to the possibility that it could affect some populations with substance use disorders or HIV particularly hard. Because it attacks the lungs, COVID-19 could be an especially serious threat to those with histories of smoking tobacco or marijuana or of vaping. People who use opioids or methamphetamine may also be vulnerable due to those drugs’ effects on respiratory and pulmonary health and potential effects on immune mechanisms. Likewise, those with HIV may be affected if their immune function is compromised. Additional social and environmental factors associated with drug use may worsen the transmission and treatment of COVID-19, especially among individuals who experience homelessness or incarceration, which is more common among those with a substance use disorder.

Research Objectives

In order to rapidly improve our understanding of the risks, prevalence, and available control measures for 2019-nCoV in substance using or HIV-affected populations, NIDA is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:

  • Research to determine whether substance use (especially smoking tobacco or marijuana, vaping, opioids and other drug use) is a risk factor for the onset and progression of COVID-19.
  • Research on how HIV among persons who use substances may impact the onset and progression of COVID-19.
  • Research to understand system-level responses to COVID-19 prevention and risk mitigation in secure settings such as prisons and jails, with a particular emphasis on detainees with substance use disorder (SUD). For example:
    • Interactions of COVID-19 treatment with SUD treatments, including medications for opioid use disorders
    • Strategies for integrating COVID-19 and other infectious disease screening, prevention, and treatment protocols with SUD treatment and other health services.
  • Research to understand the respiratory effects of SARS-CoV-2 infection among individuals with substance use disorders (SUD); in particular those with nicotine, marijuana, opioid, and methamphetamine use disorders.
  • Research to understand how the respiratory effects of COVID-19 influences the rate of opioid overdoses both in pain patients as well as patients with an opioid use disorders and also to assess how it influences the outcomes for naloxone interventions for overdose reversal
  • Research to develop therapeutic approaches for comorbid SARS-CoV-2 infection and SUDs.
  • Research to evaluate drug-drug interaction of medications to treat SARS-CoV-2 and substances of abuse or medications to treat SUDs.
  • Research to understand system- or organizational-level responses to identify, prevent, or mitigate the impact of COVID-19 in service settings that serve vulnerable populations, including people who are homeless or unstably housed.
  • Research to understand and mitigate the impact of COVID-19 in methadone treatment programs and syringe exchange services.
  • Research on how potential overcrowding of emergency departments and health services will impact the treatment of opioid overdoses and of opioid use disorder
  • Research using ongoing studies to understand the broad impacts of COVID-19 (e.g., school closures, food insecurity, anxiety, social isolation, family loss) on neurodevelopment, substance use, substance use disorders, and access to addiction treatment.

Application and Submission Information

Applications in response to this NOSI must be submitted using the following targeted funding opportunity:

  • PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
  • PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.
  • The funding instrument, or activity code, will be the same as the parent award.

When developing applications in response to this NOSI, all instructions in the SF424 (R&R) Application Guide must be followed, with the following additions:

  • The Research Strategy section of the application is limited to 6 pages.
  • The award project period of the submission must not exceed two years.
  • Application budgets are generally limited to no more than $100,000 direct costs per year. Should the proposed research require a higher budget, the applicant should consult with the program official assigned to the parent award and include a strong justification for the larger budget in the supplement application. The proposed budget must reflect the actual needs of the proposed project.
  • The parent award must be active when the application is submitted. The project and budget periods must be within the currently approved project period for the existing parent award.
  • Applications will be accepted on a rolling basis through March 31, 2021 by 5:00 PM local time of the applicant organization. This NOSI expires on April, 1, 2021.
  • All applications (including those for multi-project activity codes) must be submitted electronically using a single-project application form package:
    • Administrative supplement applications to PA-18-591 must use the application form package with the Competition ID of “FORMS-E-ADMINSUPP-RESEARCH". This FOA will be reissued with a “FORMS-F-ADMINSUPP-RESEARCH” package on May 25, 2020. Submissions to PA-18-591 must be completed by June 25, 2020 (see NOT-OD-20-026 for details.) Submissions to the reissued FOA will be accepted on or after May 25, 2020 through the expiration date of this Notice. In addition, the process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.
    • Competitive revision applications to PA-18-935 must use the application form package with the Competition ID of “NOT-DA-20-047-FORMS-E." This FOA will be reissued with a “NOT-DA-20-047-FORMS-F” package on May 25, 2020. Submissions to PA-18-935 must be completed byJune 25, 2020. Submissions to the reissued FOA will be accepted on or after May 25, 2020 through the expiration date of this Notice
  • IMPORTANT: For funding consideration, all applicants must designate “NOT-DA-20-047” (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. Applications without this information in Box 4b will not be considered for this initiative.
  • Investigators planning to submit an application in response to the NOSI are strongly encouraged to contact the program officers listed below to discuss the proposed project in the context of the parent award.

Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI initiative.

 

Inquiries

Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.

Scientific/Research Contact(s)

MeLisa Creamer, PhD, MPH
Division of Epidemiology, Services, and Prevention Research
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-1933
Email: melisa.creamer@nih.gov

Shwe Gyaw, MD
Division of Therapeutics & Medical Consequences
National Institute on Drug Abuse
Telephone: 301-827-5924
Email: shwe.gyaw@nih.gov

Financial/Grants Management Contact(s)

Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: pfleming@mail.nih.gov

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

 

 

 

[#DIV28SUPER] Postdoctoral Associate Addiction Recovery Research Center Fralin Biomedical Research Institute at VTC Virginia Tech

Postdoctoral Associate

Addiction Recovery Research Center

Fralin Biomedical Research Institute at VTC

Virginia Tech

 

Imagine working in a stimulating environment where you will be a part of cutting-edge research discoveries where

  • multiple NIH grants fund a variety of diverse interdisciplinary and translational research projects 
  • invaluable grant-writing experience is gained and encouraged
  • you will work closely with some of the leading researchers in addiction, behavioral economics, and neuroimaging
  • you are encouraged to pitch your own ideas for meaningful research projects that fall within the scope of the lab 
  • postdoctoral associates average 5 published manuscripts per year

     

Imagine a growing research institute that attracts leading scientists from across the nation -- The Fralin Biomedical Research Institute at VTC (formerly known as the Virginia Tech Carilion Research Institute) is a unique public-private partnership that leverages Virginia Tech's world-class strength in basic sciences, bioinformatics, and engineering with Carilion Clinic's highly experienced medical staff and a rich history in medical education. Virginia Tech Carilion (VTC) improves human health and quality of life by providing leadership in medical education and biomedical and clinical research.  This academic health center was recently renamed Fralin Biomedical Research Institute at VTC in honor of the $50 million donation provided by the generosity of Heywood and Cynthia Fralin to progress the growth of this institute and its contributions to medical and research advancements.

 

Position Summary:  The Addiction Recovery Research Center (ARRC) is directed by Dr. Warren K. Bickel, an accomplished scholar and researcher whose work is frequently cited and receives national and international recognition. This position will work primarily on NIH funded projects that are providing new information about substance and alcohol use disorders, health behaviors, and decision-making. Several projects are focusing on the use of the Experimental Tobacco Marketplace to investigate choice behavior among nicotine users from a behavioral economics framework. Other projects are focusing on treatments for alcohol use disorder and the examination of Episodic Future Thinking on alcohol self-administration and with real-time fMRI. Moreover, ARRC has ongoing projects to examine long-term recovery from addiction. The position is well suited for individuals interested in technological and behavioral economic applications to addiction and health behavior. This postdoctoral position will also be involved in developing pilot research programs in the research areas of the lab and will be expected to help develop these additional projects.

 

Appointment:  1-3 yrs.

 

Eligibility: Candidates are expected to have a solid background in psychology, behavioral economics, neuroscience, and/or addiction or health behaviors research. In addition, experience with behavior analysis, clinical trials, and/or neuroimaging is highly desirable. The successful candidate will possess a PhD in psychology, neuroscience, or appropriate related discipline and have a record of research excellence as indicated by peer-reviewed publications and presentations.  

 

Benefits: Full-time annual salary, medical insurance coverage, and travel funds supported by NIH grants. Translational research training and career development opportunities are provided as part of this position.

 

For more information:  Contact Ms. Patsy Marshall (patsym@vtc.vt.edu).

 

To apply: Send cover letter, curriculum vitae, and a statement of research interests to:  Dr. Warren K. Bickel c/o Ms. Patsy Marshall (patsym@vtc.vt.edu). Applications will be reviewed on an ongoing basis.

 

About us: The Addiction Recovery Research Center (ARRC) was established in 2011 as part of the Virginia Tech Carilion Research Institute (VTCRI). The existing facilities and research teams are world-class and focus on transdisciplinary research on the scientific underpinnings of health and a range of diseases and substance use disorders. A new biomedical expansion is currently being constructed and will include additional research laboratories to focus on brain health and disorders, biomaterials-body device interfaces, cardiovascular sciences, cancer, metabolism and obesity, and infectious disease and immunity. The Fralin Biomedical Research Institute at VTC represents a new model for biomedical and behavioral science in which creative scientists can approach major problems with breadth and depth in a nurturing and intellectually challenging environment.

 

About Roanoke, Virginia: Roanoke, Virginia is located in Southwest Virginia in the foothills of the Appalachian Mountains and accessible by the Blue Ridge Parkway. Roanoke is a vibrant community with an active downtown full of restaurants, theaters, museums, and an amphitheater that is home to many seasonal festivals and music events. Roanoke also offers great opportunities for an active outdoor lifestyle with 30 miles of greenway connecting charming neighborhoods and beautiful parks along the Roanoke River. Roanoke is one of two cities in the nation to earn the All-American City Award a record seven times.

 

 

 

 



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
Departments of Behavioral Science, Psychiatry and Psychology
Center on Drug and Alcohol Research
University of Kentucky

Director
Regulatory Knowledge and Support Core-Center for Clinical and Translational Science
Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.